Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevention of ASCVD. However, statins may not be sufficient in decreasing LDL cholesterol levels and pose a significant on-treatment residual risk of major cardiovascular events (i.e., residual cholesterol risk) according to meta-analyses of statin trials. Current guidelines for cholesterol management to achieve additional LDL cholesterol reduction and reduce ASCVD risk recommend two hyperlipidemic agents besides statins. Use of ezetimibe, a cholesterol absorption inhibitor, leads to additional LCL cholesterol reduction and decreased ASCVD risk, when added to statin therapy, without raising significant safety concerns. Furthermore, in combination with a mild-to-moderate statin intensity, ezetimibe is used in situations of statin-associated adverse effects such as myalgia and the combination therapy is relatively safer. Monoclonal antibody of proprotein convertase subtilisin/kexin type 9 (PCSK9), alirocumab, and evolocumab, have been approved to lower LDL cholesterol level. While there are drawbacks to the use of PCSK9 inhibitors, including high cost and adverse events such as injection site reaction, they significantly decreased serum LDL cholesterol levels and thereby ASCVD risks when added to maximally tolerated statin therapy.
Abstract
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevention of ASCVD. However, statins may not be sufficient in decreasing LDL cholesterol levels and pose a significant on-treatment residual risk of major cardiovascular events (i.e., residual cholesterol risk) according to meta-analyses of statin trials. Current guidelines for cholesterol management to achieve additional LDL cholesterol reduction and reduce ASCVD risk recommend two hyperlipidemic agents besides statins. Use of ezetimibe, a cholesterol absorption inhibitor, leads to additional LCL cholesterol reduction and decreased ASCVD risk, when added to statin therapy, without raising significant safety concerns. Furthermore, in combination with a mild-to-moderate statin intensity, ezetimibe is used in situations of statin-associated adverse effects such as myalgia and the combination therapy is relatively safer. Monoclonal antibody of proprotein convertase subtilisin/kexin type 9 (PCSK9), alirocumab, and evolocumab, have been approved to lower LDL cholesterol level. While there are drawbacks to the use of PCSK9 inhibitors, including high cost and adverse events such as injection site reaction, they significantly decreased serum LDL cholesterol levels and thereby ASCVD risks when added to maximally tolerated statin therapy.
참고문헌 (42)
- Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Roth GA, "Global and regional patterns in cardiovascular mortality from 1990 to 2013", Circulation, 132, pp.1667~1678 (2015)
- 안창호, "New Drugs for Treating Dyslipidemia: Beyond Statins", Diabetes and Metabolism Journal, 39(2), pp.87~94 (2015), 대한당뇨병학회
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Catapano AL, "2016 ESC", EAS Guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
- 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]
- Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
- Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Baigent C, "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial", Lancet, 377, pp.2181~2192 (2011)
- Phan BA, "Ezetimibe therapy: mechanism of action and clinical update", Vasc Health Risk Manag, 8, pp.415~427 (2012)
- Pandor A, "Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials", J Intern Med, 265, pp.568~580 (2009)
- Descamps O, "Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients", Atherosclerosis, 240, pp.482~489 (2015)
- Rossebø AB, "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis", N Engl J Med, 359, pp.1343~1356 (2008)
- Kato ET, "Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)", J Am Heart Assoc, 6, pp.e006901~ (2017)
- Giugliano RP, "Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus:results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)", Circulation, 137, pp.1571~1582 (2018)
- Pokharel Y, "Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)", Circ Cardiovasc Qual Outcomes, 10, pp.e003201~ (2017)
- Bohula EA, "Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)", Circulation, 136, pp.2440~2450 (2017)
- Bruckert E, "Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study", Cardiovasc Drugs Ther, 19, pp.403~414 (2005)
- Cohen JD, "Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users", J Clin Lipidol, 6, pp.208~215 (2012)
- Saxon DR, "statin intolerance: a literature review and management strategies", Prog Cardiovasc Dis, 59, pp.153~164 (2016)
- Wilson PW, "Systematic review for the 2018AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Wu H, "Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials", Endocrine, 60, pp.229~239 (2018)
- Deushi M, "Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome", FEBS Lett, 581, pp.5664~5670 (2007)
- Kosoglou T, "Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions", Clin Pharmacokinet, 44, pp.467~494 (2005)
- Sullivan D, "Effect of a monoclonal antibody to PCSK9on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial", JAMA, 308, pp.2497~2506 (2012)
- Stein EA, "Effect of a monoclonal antibody to PCSK9, REGN727", SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial, 2012, pp.380, 29~36
- Reiss AB, "PCSK9 in cholesterol metabolism: from bench to bedside", Clin Sci (Lond), 132, pp.1135~1153 (2018)
- Abifadel M, "Mutations in PCSK9 cause autosomal dominant hypercholesterolemia", Nat Genet, 34, pp.154~156 (2003)
- Lagace TA, "PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells", Curr Opin Lipidol, 25, pp.387~393 (2014)
- Ridker PM, "Lipid-reduction variability and antidrug-antibody formation with bococizumab", N Engl J Med, 376, pp.1517~1526 (2017)
- Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)
- Ray KK, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol", N Engl J Med, 376, pp.1430~1440 (2017)
- Koren MJ, "Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial", Circulation, 129, pp.234~243 (2014)
- Karatasakis A, "Effect of pcsk9inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials", J Am Heart Assoc, 6, pp.e006910~ (2017)
- Hlatky MA, "PCSK9 Inhibitors: Economics and Policy", J Am Coll Cardiol, 70, pp.2677~2687 (2017)
- Kazi DS, "Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial", JAMA, 318, pp.748~750 (2017)
- Virani SS, "Estimation of eligibility for proprotein convertase subtilisin", kexin type 9 inhibitors and associated costs based on the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk):insights from the Department of Veterans Affairs, 2017, pp.135, 2572~2574
- Arrieta A, "Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial", JAMA Cardiol, 2, pp.1369~1374 (2017)
- Kastelein JJ, "Simvastatin with or without ezetimibe in familial hypercholesterolemia", N Engl J Med, 358, pp.1431~1443 (2008)
- Nicholls SJ, "Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial", JAMA, 316, pp.2373~2384 (2016)